Elrexfio (elranatamab-bcmm) - Pfizer
Elrexfio: Expiry of patents in US in 2036 with term extension until 2037 (Pfizer) - Mar 4, 2024 - Annual Report 2023: Expiry of patents in EU/Japan in 2036 
Patent Hematological Malignancies • Multiple Myeloma • Oncology
https://d18rn0p25nwr6d.cloudfront.net/CIK-0000078003/1447e045-6320-4de3-a603-248c700cf342.pdf
 
Mar 4, 2024
 
 
74f83f69-7c7c-428d-a1cd-d1f15809ddfd.png